Nature Communications (Nov 2017)
Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling
- Inma M. Berenjeno,
- Roberto Piñeiro,
- Sandra D. Castillo,
- Wayne Pearce,
- Nicholas McGranahan,
- Sally M. Dewhurst,
- Valerie Meniel,
- Nicolai J. Birkbak,
- Evelyn Lau,
- Laurent Sansregret,
- Daniele Morelli,
- Nnennaya Kanu,
- Shankar Srinivas,
- Mariona Graupera,
- Victoria E. R. Parker,
- Karen G. Montgomery,
- Larissa S. Moniz,
- Cheryl L. Scudamore,
- Wayne A. Phillips,
- Robert K. Semple,
- Alan Clarke,
- Charles Swanton,
- Bart Vanhaesebroeck
Affiliations
- Inma M. Berenjeno
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- Roberto Piñeiro
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- Sandra D. Castillo
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- Wayne Pearce
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- Nicholas McGranahan
- The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UCL Cancer Institute and Hospitals
- Sally M. Dewhurst
- The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UCL Cancer Institute and Hospitals
- Valerie Meniel
- European Cancer Stem Cell Research Institute, Cardiff University
- Nicolai J. Birkbak
- The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UCL Cancer Institute and Hospitals
- Evelyn Lau
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- Laurent Sansregret
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- Daniele Morelli
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- Nnennaya Kanu
- The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UCL Cancer Institute and Hospitals
- Shankar Srinivas
- Department of Physiology Anatomy and Genetics, University of Oxford
- Mariona Graupera
- Vascular Signalling Laboratory, Institut d´Investigació Biomèdica de Bellvitge (IDIBELL)
- Victoria E. R. Parker
- Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital
- Karen G. Montgomery
- Cancer Biology and Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre
- Larissa S. Moniz
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- Cheryl L. Scudamore
- Mary Lyon Centre, MRC Harwell
- Wayne A. Phillips
- Cancer Biology and Surgical Oncology Research Laboratory, Peter MacCallum Cancer Centre
- Robert K. Semple
- Institute of Metabolic Science, University of Cambridge, Addenbrooke’s Hospital
- Alan Clarke
- European Cancer Stem Cell Research Institute, Cardiff University
- Charles Swanton
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- Bart Vanhaesebroeck
- UCL Cancer Institute, Paul O’Gorman Building, University College London
- DOI
- https://doi.org/10.1038/s41467-017-02002-4
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 15
Abstract
Activated PI3K causes cancer, but the role of active PI3K mutations in early stages of malignancy are unclear. Here, the authors show in a mouse model that active PI3K induces centrosome amplification via AKT, ROCK, CDK2/Cyclin E and nucleophosmin, and increased tolerance of genome doubling.
